BRIDGEBIO PHARMA INC. - COMMON STOCK

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

28 4 2025 05:00:00 提供 Nasdaq GlobeNewswire

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

22 4 2025 07:30:36 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11 4 2025 16:01:00 提供 Nasdaq GlobeNewswire

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

31 3 2025 10:00:00 提供 Nasdaq GlobeNewswire

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

27 3 2025 07:00:00 提供 Nasdaq GlobeNewswire

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

24 3 2025 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 3 2025 16:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Announces CFO Succession

17 3 2025 16:01:00 提供 Nasdaq GlobeNewswire

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

26 2 2025 02:49:38 提供 Nasdaq GlobeNewswire

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

24 2 2025 16:09:42 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

20 2 2025 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

13 2 2025 16:01:00 提供 Nasdaq GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

11 2 2025 09:21:48 提供 Nasdaq GlobeNewswire

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

13 1 2025 11:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

08 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

13 12 2024 07:18:03 提供 Nasdaq GlobeNewswire

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

22 11 2024 19:11:30 提供 Nasdaq GlobeNewswire

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

18 11 2024 11:15:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

12 11 2024 07:30:01 提供 Nasdaq GlobeNewswire

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

05 11 2024 07:30:00 提供 Nasdaq GlobeNewswire